Objective: The aim of this study was to evaluate the efficacy, reasons for switching and drug survival of TNF-α inhibitors (TNFis) used as first- and second-line drugs in ankylosing spondylitis (AS).
Methods: Data on patients suffering from AS and treated with at least one TNFi between November 2005 and 2013 were extracted retrospectively from the database of a single clinical centre. Beside demographic data, the disease activity measured by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), the response rates (BASDAI50), reasons for switching and survival curves of TNFis were analysed in general and in subgroups of patients treated with each of the available TNFis. The reasons for switching were defined as inefficacy, side effects of the given drug, patient's request and occurrence of extra-articular manifestations.
Results: Altogether, 175 patients were on TNFis and 77 of them received at least two TNFis. The patients' age at the initiation of the first TNFi was higher among switchers compared to non-switchers (42.5 ± 12.6 vs. 38.8 ± 11.2 years, p = 0.049); otherwise, gender, disease duration and initial disease activity had no influence on the risk of switching. The decrease of the BASDAI was similar among non-switchers and switchers using either the first or second TNFi, but the response rates to the first and second TNFi were worse in switchers than in non-switchers. Following the failure of the first TNFi, the retention on therapy was unfavourable, especially in patients on infliximab after 1 year of treatment. The main reason for switching from the first drug was inefficacy. The frequency of side effects that led to switching was higher in the infliximab group than in patients treated with other agents.
Conclusion: Although the retention rate to a second-line TNFi was somewhat worse than that to the first-line TNFi, the switching of TNFis is a good therapeutic option in AS patients who failed to respond to the first TNFi.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10198-014-0598-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Genetic Commonalities Between Metabolic Syndrome and Rheumatic Diseases Through Disease Interactome Modules.
J Cell Mol Med
January 2025
Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China.
This study aims to elucidate the potential genetic commonalities between metabolic syndrome (MetS) and rheumatic diseases through a disease interactome network, according to publicly available large-scale genome-wide association studies (GWAS). The analysis included linkage disequilibrium score regression analysis, cross trait meta-analysis and colocalisation analysis to identify common genetic overlap. Using modular partitioning, the network-based association between the two disease proteins in the protein-protein interaction set was divided and quantified.
View Article and Find Full Text PDFCOping with Rheumatic Stressors (CORS) questionnaire: validated German translation and cross-cultural adaptation for patients with axSpA.
J Patient Rep Outcomes
January 2025
Ruhr-Universität Bochum, Bochum, Germany.
Background: Patients with Rheumatic and Musculoskeletal Diseases, including axial spondyloarthritis (axSpA), may suffer from stressors like pain and functional impairments leading to limitations in their self-perceived health status. The COping with Rheumatic Stressors (CORS) questionnaire was developed to analyze how patients cope with these stressors. The CORS is currently not available in German.
View Article and Find Full Text PDFAnterior and Posterior Ocular Changes in Patients with Active and Inactive Ankylosing Spondylitis.
Med Sci Monit
January 2025
Deparment of Ophthalmology, Mengücek Gazi Training and Research Hospital, Erzincan Binali Yıldırım University, Erzincan, Turkey.
BACKGROUND The 6-item Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a method for evaluating disease activity in ankylosing spondylitis (AS). This study included 78 patients with active and inactive AS and aimed to evaluate anterior and posterior segment ocular changes. MATERIAL AND METHODS Seventy-eight patients and 70 control subjects were enrolled in this study.
View Article and Find Full Text PDFDiagnostic efficacy of dual-energy CT virtual non-calcium technique in the diagnosis of bone marrow edema of sacroiliac joints in ankylosing spondylitis.
J Orthop Surg Res
January 2025
Medical school, Kunming University of Science and Technology, Kunming, Yunnan, China.
Objective: In-depth investigation of the diagnostic performance of dual-energy CT (DECT) virtual non-calcium (VNCa) technique for sacroiliac joint bone marrow edema (BME) in patients with ankylosing spondylitis(AS).
Methods: A total of 42 patients with AS)who underwent sacroiliac joint MRI and DECT scans on the same day at our Rheumatology and Immunology Department between August 2022 and June 2023 were selected. Using MRI as the reference standard, the presence of BME on the iliac and sacral surfaces was evaluated, resulting in the categorization of patients into BME-positive and BME-negative groups.
Genetic Risk of Ankylosing Spondylitis and Second-Line Therapy Need in Crohn's Disease: A Mendelian Randomization Study.
J Clin Med
December 2024
Internal Medicine B, Sheba Medical Centre, Ramat Gan 5262000, Israel.
Crohn's disease (CD) and Ankylosing Spondylitis (AS) are chronic conditions with overlapping inflammatory pathways. This research investigates the genetic association between AS and the requirement for more aggressive therapeutic interventions in CD, suggesting a likelihood of increased severity in CD progression among individuals diagnosed with AS. This study utilized two-sample Mendelian randomization (TSMR) to analyze GWAS datasets for AS and CD requiring second-line treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!